Pomerantz LLP is investigating claims on behalf of investors of  Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

This comes at a challenging time for gene therapies, as multiple serious AEs and fatalities have been recently reported.

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...

Robotic therapy animals could open new doors for trauma recovery, autism support, and mental health care at scale.

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

Sami Corwin, an analyst at William Blair, maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on ...

A New Jersey biotech company has paused a gene therapy trial after a participant had an unexpected adverse event and later died from a sudden, severe infection.  Rocket Pharmaceuticals said the ...

Jefferies analyst Andrew Tsai downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to ...